Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
Florence Pédeutour(Centre National de la Recherche Scientifique), Claude Turc‐Carel(Centre National de la Recherche Scientifique), Fabiola Minoletti(Fondazione IRCCS Istituto Nazionale dei Tumori), N Ayraud(Université Côte d'Azur), P. Combemale(Centre Léon Bérard), Gisèle Barcelo(Université Côte d'Azur), Marie‐José Terrier‐Lacombe(Institut Gustave Roussy), Marie‐Pierre Simon(Centre Antoine Lacassagne), Gabriella Sozzi(Fondazione IRCCS Istituto Nazionale dei Tumori)
Cited by 194
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192
Neurofibromatosis 1 French national guidelines based on an extensive literature review since 1966
|Orphanet Journal of Rare Diseases|2020|188